SASKATOON, July 28, 2015 /CNW/ - Cannabis is a personalized medicine, and as a result many patients need to try a few different varieties or products before finding the one that works best for their individual condition. Today, CanniMed Ltd. is offering patients flexibility and cost-efficiency in their purchasing by introducing five gram packaging available for all seven varieties of CanniMed's pharmaceutical-grade cannabis.
"Our CanniMed starter program that offered patients a five gram bottle of three distinct products, along with a portable vaporizer and our CanniMed logbook, was a welcome addition to physicians and patients trying to dial in their medical cannabis treatment needs," said Brent Zettl, President and CEO of CanniMed Ltd. "The expansion of the five gram bottles to our entire product line offers patients the additional flexibility with their ordering and medication needs."
All CanniMed products are in stock and now available in five gram, 10 gram and 30 gram increments.
About CanniMed and Prairie Plant Systems
CanniMed Ltd. was the first producer to be licensed under the new Marihuana for Medical Purposes Regulations (MMPR). Our pharmaceutical-grade marijuana is produced under Good Manufacturing Practices (GMP) regulations, the criteria used to manufacture all pharmaceuticals in Canada. Our primary focus is on patient safety, undertaken by strictly following a 281 point quality control process.
CanniMed's parent company, Prairie Plant Systems Inc. was the sole supplier to Health Canada under the former medical marijuana system for 13 years, and has been producing safe and consistent medical marijuana for thousands of Canadian patients, with no incident of diversion.
These two companies together have created the leading medical cannabis company in Canada with a strong corporate priority to design and execute clinical research that will close the gap between the anecdotal benefit and evidence based medicine in order to standardize care. Our Canadian-grown cannabis is already leading the way in standardizing care and has been used in a published clinical trial demonstrating the efficacy of smoked cannabis for chronic pain,i which was used in the development of the Canadian Pain Society's Pharmacological management of chronic neuropathic pain: Revised consensus statement positioning medical cannabis as third line treatment for neuropathic pain.ii
i Ware, M.A., Wang, T., Shapiro, S., Robinson, A. and others. (2010) Smoked Cannabis for Chronic Pain: a Randomized Controlled Trial. Canadian Medical Association Journal (CMAJ). 182:E694-E701.
ii Moulin, D.E., Boulanger, A., Clark A.J., Dao, T. and others. (2014) Pharmacological Management of Chronic Neuropathic Pain: Revised Consensus Statement from the Canadian Pain Society. Pain Research and Management. Nov-Dec; 19(6): 328–335.
SOURCE CanniMed Ltd.
Image with caption: "CanniMed Ltd. (CNW Group/CanniMed Ltd.)". Image available at: http://photos.newswire.ca/images/download/20150728_C5301_PHOTO_EN_459903.jpg
For further information: CanniMed Ltd., Phone: 1-855-787-1577, Email: firstname.lastname@example.org; Dara Willis, Dara Willis Communications, Mobile: 416-836-9272, Email: email@example.com